# Invirsa

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/invirsa

- Industry: Biotechnology
- Headquarters: Columbus, US
- Website: www.invirsa.com
- Total disclosed funding: $6.7M
- Latest round: Series B (Dec 21, 2022)
- Investors on record: 4

## About

Invirsa, Inc., based in Columbus, Ohio, focuses on developing innovative treatments for ocular conditions, enhancing the body's response to DNA damage, particularly from sulfur mustard gas exposure.Invirsa, Inc. specializes in advancing therapeutic solutions for ocular conditions. Founded in 2016 by Robert Shalwitz, the company has undergone strategic developments to align its offerings with healthcare demands. It has raised a total of USD 1.00 mn through its SERIES B funding round as of November 14, 2023, with a current valuation of USD 32.819 mn. The firm has successfully completed five deals to date, positioning itself for further growth in the biotechnology sector.Invirsa’s primary product offering is its lead compound, INV-102, which enhances the body’s ability to respond to DNA damage. This innovative treatment is specifically designed to address ocular conditions resulting from DNA injury, including those caused by sulfur mustard gas exposure. INV-102 functions by stabilizing cellular structure at critical moments of DNA repair, thereby facilitating a more effective healing process. The compound targets conditions such as viral and bacterial conjunctivitis, which affect millions of individuals annually, particularly in the United States. With a significant portion of conjunctivitis cases being viral and lacking an approved treatment, INV-102 aims to fill this gap and provide relief to a diverse customer base that includes healthcare providers and patients across the U.S. market and potentially beyond.Invirsa’s revenue structure is primarily derived from partnerships and funding arrangements, notably a USD 29.6 mn collaboration with BARDA aimed at advancing the development of INV-102 for ocular conditions. This strategic partnership is indicative of the company’s approach to securing financial support while bringing its innovative product to market. Revenue generation may also involve B2B transactions with healthcare providers who will ultimately prescribe INV-102 to patients suffering from various ocular injuries. By aligning with government funding initiatives and targeting significant healthcare challenges, Invirsa positions itself to establish a robust revenue stream as INV-102 moves closer to commercial availability. The company’s focus on addressing critical health issues suggests a structured pathway for revenue through partnerships and eventual sales of its flagship product.In November 2023, Invirsa, Inc. raised USD 1 mn in SERIES B funding, which will be utilized to enhance the development and market introduction of INV-102. The company is committed to expanding its product line and addressing additional ocular health needs. Plans are in place to explore new geographic markets, particularly targeting regions with high incidences of ocular conditions, by 2024. The capital raised will support these initiatives, facilitating the development of new treatment modalities and potentially increasing the company’s market reach.

## Funding rounds

- Series B, Dec 21, 2022, $6M — JumpStart, CincyTech, Rev1 Ventures, JobsOhio
- Seed, Nov 7, 2017, $0.5M — CincyTech, Rev1 Ventures
- Seed, Jul 15, 2016, $0.1M — Rev1 Ventures

## Investors

- Rev1 Ventures (https://capitalatlas.ai/funds/rev1-ventures) — Seed, Series B
- CincyTech (https://capitalatlas.ai/funds/cincytech) — Seed, Series B
- JumpStart (https://capitalatlas.ai/funds/jumpstart) — Series B
- JobsOhio (https://capitalatlas.ai/funds/jobsohio) — Series B